In each organ, the quantities of CD45+ immune cells were significantly increased in SCLC mice treated with the ERBB2 inhibitor, compared to vehicle-treated SCLC mice (Fig. 6c–e). This evidence concerns the gene PTPRC and small cell lung carcinoma.